Key result
On-X mechanical mitral valves show comparable long-term outcomes to bioprostheses in patients over 65.
Why the study?
To compare early and long-term clinical outcomes of bioprosthetic versus mechanical (On-X) mitral valve replacement in patients aged 65 years and older.
Does mechanical (On-X) mitral valve replacement improve long-term clinical outcomes compared to bioprosthetic valves in patients aged 65 years and older requiring isolated MVR?
Cohort
No
Does mechanical (On-X) mitral valve replacement improve long-term clinical outcomes compared to bioprosthetic valves in patients aged 65 years and older requiring isolated MVR?
p-value: p=.170
In patients 65 years and older undergoing isolated mitral valve replacement, the On-X mechanical valve provides comparable long-term clinical outcomes to bioprosthetic valves.
Hypothesis-generating for On-X mechanical valves in elderly isolated MVR; prospective trials needed before practice change.
Objective: To compare early and long-term clinical outcomes of bioprosthetic versus mechanical (On-X) mitral valve replacement (MVR) in patients aged 65 years and older. Methods: This single-center retrospective study included consecutive patients equal to or older than 65 years underwent isolated MVR from 2005 to 2023. A propensity score-matched analysis was performed to compare early- and long-term clinical outcomes between patients with bioprostheses and mechanical On-X valve. Results: = .170). The 1-, 5-, and 10-year freedom from reoperation, endocarditis, pacemaker implantation, and hemorrhagic events were comparable between the 2 groups. Conclusions: In patients older than 65 years requiring isolated MVR, the use of On-X mechanical prosthesis showed comparable long-term outcomes over bioprostheses.
No takes yet. Share an insight, caveat, or question.
Piperata et al. (2025) conducted a cohort in Isolated mitral valve replacement. Mechanical (On-X) mitral valve replacement vs. Stented bioprosthetic valves was evaluated on Early- and long-term clinical outcomes (including freedom from reoperation, endocarditis, pacemaker implantation, and hemorrhagic events) (p=.170). In patients aged ≥65 years requiring isolated mitral valve replacement, On-X mechanical prostheses showed comparable long-term outcomes to bioprostheses (P=.170).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: